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DNA methylation age is accelerated in
alcohol dependence
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Steve Horvath4,5, Zachary A. Kaminsky6,7 and Falk W. Lohoff1
Abstract
Alcohol dependence (ALC) is a chronic, relapsing disorder that increases the burden of chronic disease and
significantly contributes to numerous premature deaths each year. Previous research suggests that chronic, heavy
alcohol consumption is associated with differential DNA methylation patterns. In addition, DNA methylation levels at
certain CpG sites have been correlated with age. We used an epigenetic clock to investigate the potential role of
excessive alcohol consumption in epigenetic aging. We explored this question in five independent cohorts, including
DNA methylation data derived from datasets from blood (n= 129, n= 329), liver (n= 92, n= 49), and postmortem
prefrontal cortex (n= 46). One blood dataset and one liver tissue dataset of individuals with ALC exhibited positive
age acceleration (p < 0.0001 and p= 0.0069, respectively), whereas the other blood and liver tissue datasets both
exhibited trends of positive age acceleration that were not significant (p= 0.83 and p= 0.57, respectively). Prefrontal
cortex tissue exhibited a trend of negative age acceleration (p= 0.19). These results suggest that excessive alcohol
consumption may be associated with epigenetic aging in a tissue-specific manner and warrants further investigation
using multiple tissue samples from the same individuals.
Introduction
Alcohol dependence (ALC) is a chronic, relapsing dis-
order that significantly impacts personal and public
health. ALC affects ~29.1% of individuals during their
lifetime and is a leading cause of premature death in the
United States1. In fact, between 2006 and 2010, chronic
diseases caused by excessive alcohol use (such as hepatitis,
hypertension, liver cancer, and stroke) resulted in 38,584
deaths and 864,351 years of potential life lost2.
Chronic alcohol use affects multiple tissues, including
the brain and liver. Previous results found that ALC may
be associated with accelerated decline in gray matter
volume in the brain. In the prefrontal cortex (PFC), this
decline could impact functioning, including cognitive
abilities3. In addition, in a study using diffusion tensor
imaging, middle-aged adults with ALC had reduced pre-
frontal white matter integrity and slower processing speed
as compared to healthy controls4. Excessive alcohol use
also has harmful effects on liver function that can lead to
premature death due to alcoholic cirrhosis and liver
cancer5.
Although the underlying pathophysiology is poorly
understood, multiple genetic and epigenetic factors have
been implicated in ALC and numerous chronic disease
outcomes6. In fact, the field of epigenetics has shown that
environmental exposures may lead to changes in gene
expression that are not related to changes in the DNA
sequence; these alterations occur via mechanisms such as
DNA methylation and histone modification7. Specifically,
DNA methylation profiles have been shown to differ
between individuals who consume excessive amounts of
alcohol and healthy individuals8–10.
The well-known strong associations that have been
previously established between age and DNA methylation
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profiles suggest a new way to investigate aging on a
molecular level11–13. Such research is increasingly
important, as the United States Census Bureau estimates
that the number of Americans over 65 years old will
nearly double between 2012 and 205014. A better under-
standing of molecular aging could allow for novel detec-
tion of aging-related morbidities and treatment methods,
therefore improving overall health and well-being.
A growing interest in the development of biomarkers to
study the relationship between aging and epigenetic
profiles has led to the advent of epigenetic clocks. Hor-
vath’s epigenetic clock, which is based on a weighted
average of methylation levels at 353 dinucleotide cytosine
phosphate guanine markers (CpGs), predicts DNA
methylation age. Its high correlation with chronological
age (years since birth), ability to predict all-cause mor-
tality, and its validity across various tissue types (including
blood, brain, and liver) make Horvath’s epigenetic clock a
useful tool for the study of aging, as it has the potential to
provide an accurate marker of biological age in clinical
populations12.
Given the potential role of ALC in the aging process, it
is important to gain a better understanding of this rela-
tionship on a molecular, epigenetic level. Although the
relationship between ALC and aging has not been
extensively studied using Horvath’s epigenetic clock,
Quach et al.15 found a small negative correlation of age
acceleration with moderate alcohol consumption in blood
in an analysis of behavioral and lifestyle factors15. Simi-
larly, an analysis using blood samples and a blood-specific
epigenetic clock developed by Hannum revealed acceler-
ated biological aging in light and heavy drinkers, and a
deceleration in moderate drinkers16. Although these stu-
dies provide interesting preliminary findings, more spe-
cific studies focusing on alcohol consumption as the
primary exposure are required to better understand the
role of both moderate and heavy alcohol consumption in
aging on the molecular level.
Developing an understanding of the role of ALC in the
aging process is vital, as excessive alcohol use has been
associated with numerous chronic disease outcomes and
premature death, even following prolonged periods of
sobriety17. In this study, Horvath’s epigenetic clock was
used to investigate the cumulative role of ALC in mole-
cular aging across tissue types including blood, brain, and
liver. It was hypothesized that individuals with ALC would
exhibit increased DNA methylation age acceleration as
compared with healthy controls in all tissue types.
Materials and Methods
DNA methylation age was calculated using Horvath’s
epigenetic clock12. The epigenetic clock uses an algorithm
based on 353 CpG sites to estimate DNA methylation age
and is valid across different tissue types. The residual
resulting from regressing DNA methylation age on
chronological age was used as a metric for age accelera-
tion. T-tests were used to compare age acceleration in
individuals with ALC and healthy controls. Linear
regression was used to control for sex, where age accel-
eration was the dependent variable, and ALC status and
sex were the independent variables13. All analyses were
conducted using R version 3.3.2 (R Foundation for Sta-
tistical Computing, Vienna, Austria) on the National
Institutes of Health (NIH) Biowulf Linux cluster. Figures
were generated using GraphPhad Prism 7 (GraphPad
Software, Inc., La Jolla, CA). Analyses were performed
using independent DNA methylation datasets derived
from two datasets of blood tissue, two datasets of liver
tissue, and one dataset of PFC tissue. The Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) was
used to diagnose ALC or alcohol abuse in all datasets with
the exception of the liver dataset in which alcohol cir-
rhosis was used as a proxy for ALC. Detailed descriptions
can be found below.
Description of datasets
NIAAA blood sample
Fifty-nine participants with a diagnosis of ALC and 70
healthy volunteers were recruited to the National Institute
on Alcohol Abuse and Alcoholism (NIAAA) at the
National Institutes of Health (NIH), USA. The study was
approved by the Institutional Review Board of the NIAAA
and was in accordance with the Declaration of Helsinki.
All individuals provided written informed consent and
were compensated for their participation. The DSM-IV
Structured Clinical Interview for Diagnosis was used to
diagnose ALC18. All participants provided a blood sample.
DNA methylation was measured using the Illumina
Human Methylation 450 (HM450) beadchip microarrays
(Illumina, Inc., San Diego, CA). The wateRmelon package
in R was used to process the raw Illumina microarray
data. Raw data were trimmed of probes failing quality
assessment and a known list of 32,323 cross-reactive
probes, followed by scale-based data correction for Illu-
mina type I relative to type II probes. Methylated and
unmethylated intensity values were then quantile nor-
malized separately before the calculation of the β-value
based on the following definition: β-value= (signal
intensity of methylation-detection probe)/(signal intensity
of methylation-detection probe+ signal intensity of non-
methylation-detection probe+ 100). Values were then
adjusted by taking the residuals of a linear model of β-
values as a function of sodium bisulfite modification
batch.
Grady Trauma Project sample (GSE72680)
The individuals in this study were part of an exploration
of genetic and environmental factors that predict the
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response to stressful life events (such as interpersonal
violence and psychosocial stress) in a predominantly
African American, urban population of low socio-
economic status19–22. DNA methylation in blood samples
was measured in 392 African American subjects using the
Illumina HM450 beadchip microarray and DNA methy-
lation β-values were downloaded from the Gene Expres-
sion Omnibus from GSE72680. Of these 392 individuals,
63 had missing alcohol phenotype data. This left 143
individuals with a diagnosis of ALC at some point in their
lifetime and 186 controls. This dataset differs from others
in that subjects were classified based on lifetime rather
than current alcohol diagnosis.
University of Minnesota LTCDS liver cirrhosis sample
Forty-six liver samples from patients with alcoholic
cirrhosis and 46 liver samples from healthy patients were
obtained through the Liver Tissue Cell Distribution Sys-
tem (LTCDS, Minneapolis, Minnesota), which was funded
by NIH Contract #HSN276200017C. DNA methylation β-
values were measured at the NIAAA using the Illumina
Infinium Methylation EPIC beadchip9.
Mayo liver cirrhosis sample (GSE 60753)
DNA methylation β-values measured using the Illumina
HM450 beadchip microarray were downloaded from the
Gene Expression Omnibus from GSE60753. Data con-
sisted of 21 liver samples with alcoholic cirrhosis and 34
normal liver samples. The original study aimed to better
understand the impact of environmental agents on DNA
methylation and ultimately liver disease23. Two liver
samples with alcoholic cirrhosis and four normal liver
samples were eliminated due to missing data on chron-
ological age. This resulted in the final analysis including
19 liver samples with alcoholic cirrhosis and 30 normal
liver samples.
Postmortem PFC tissue sample (GSE49393)
DNA methylation β-values derived from postmortem
PFC tissue were measured using Illumina HM450
beadchip microarrays from 46 PFC samples and were
downloaded from the Gene Expression Omnibus from
GSE4939324. The sample consisted of 23 subjects with
DSM-IV diagnoses of ALC (n= 9) or alcohol abuse (n=
14) and 23 age-matched controls. Additional methodol-
ogy can be found elsewhere24. The New South Wales
Tissue Resource Centre at the University of Sydney pro-
vided fresh-frozen sections of Brodmann area 9 (mainly
the dorsolateral PFC of the brain) postmortem brain tis-
sues. Ethics approval was obtained from the Sydney Local
Health Network and the University of Sydney.
Results
Horvath’s epigenetic clock was used to study epigenetic
aging in five datasets. Sample sizes and demographic
information for each sample can be found in Table 1.
Mean age ranged from 30 to 57 years old, with individuals
with ALC being slightly older than controls in most
samples. All but the Grady Trauma Project (GSE72680)
sample were predominantly male.
In the NIAAA blood sample, average age acceleration
was positive in individuals with ALC and negative in
healthy controls. This difference was highly significant (p
<0.0001). The Grady Trauma project showed a trend in
the same direction; however, age acceleration did not
significantly differ between those with a diagnosis of ALC
in their lifetime compared to those without (see Table 2
and Fig. 1 for additional information)
Similar to the blood samples, The University of Min-
nesota LTCDS sample showed positive age acceleration in
cirrhotic liver tissue and negative age acceleration in
healthy liver tissue. These results must be interpreted with
some caution; the epigenetic clock is optimized for the
Illumina 27k and 450k chips, but this data was generated
using the Illumina EPIC chip, which contains > 90% (but
not all) of the markers included on the others and thus
required the epigenetic clock algorithm to use mean
imputation. The same trend was observed in the Mayo
liver sample. The difference between groups was sig-
nificant (p= 0.0069) in the University of Minnesota
Table 1 Sample and demographic information
Chip Sample size Chronological sge mean
(SD)
Male sex count (%) Citation
Case Control Case Control Case Control
NIAAA Blood 450k 59 70 39.98 (10.02) 30.40 (8.38) 43 (72.88%) 36 (51.43%) This paper
GSE72680 (Grady Trauma Project) Blood 450k 143 186 43.70 (10.67) 40.08 (14.29) 65 (45.45%) 30 (16.13%) GSE72680
UMN LTCDS Liver EPIC 46 46 54.00 (8.52) 54.15 (8.53) 41 (89.13%) 41 (89.13%) This paper
GSE60753 (Mayo) Liver 450k 19 30 57.52 (9.64) 55.45 (17.82) 16 (84.21%) 14 (46.67%) GSE60753
GSE49393 PFC 450k 23 23 57.01 (9.26) 56.04 (9.40) 16 (69.57%) 16 (69.57%) GSE72680
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LTCDS sample, but not in the Mayo liver sample. See
Table 2 and Fig. 2 for additional information.
The dataset of PFC tissue showed negative age accel-
eration in those with a diagnosis of ALC/alcohol abuse
and positive age acceleration in healthy controls, but the
averages did not differ statistically significantly. As a result
of a small amount of missing data due to errors in mea-
surement of DNA methylation β-values on the Illumina
chip, these findings should be taken with some caution.
See Table 2 and Fig. 2 for additional information.
Linear regression models showed no significant rela-
tionship between sex and age acceleration in each of the
five samples. In addition, ALC status was significantly
associated with age acceleration in the NIAAA sample
and the University of Minnesota LTCDS sample when
controlling for sex. See Table 3 for additional information.
Lastly, exploratory analyses conducted separately for
males and females in each sample did not reveal any novel
statistically significant differences with regard to age
acceleration (data not shown).
Discussion
In this study, we explored for the first time epigenetic
aging within multiple datasets and tissue types of indivi-
duals with ALC and controls. We observed positive age
acceleration in one blood dataset and one liver tissue
dataset, but not in brain tissue. These results are parti-
cularly interesting, given the known negative effect of
prolonged excessive alcohol consumption on these parts
of the body1.
The positive age acceleration trend observed in each of
the cirrhotic liver samples was consistent with our
hypothesis. However, we expected to see a greater mag-
nitude of positive age acceleration, as both datasets con-
sisted of samples from individuals with alcoholic cirrhosis,
a severe end-stage disease caused by particularly heavy
alcohol consumption. Analyses conducted in such tissue
must be interpreted with caution, as hepatocytes found in
cirrhotic liver tissue differ significantly from healthy
hepatocytes and DNA methylation might vary5. In fact,
previous research shows that the process of alcoholic
cirrhosis may directly influence DNA methylation. In
addition, cell composition differences in cirrhotic liver
versus normal liver might account for changes in DNA
methylation age, as not only the hepatocytes, but also cells
linked to fibrosis and inflammation can be abnormal in
alcohol cirrhosis25. One way to address this limitation
would be the use of Andres Housman’s reference-free
method epigenetic clock, which accounts for cell type-
specific DNA methylation effects and different cell pro-
portions26. It remains unknown to what degree pro-
gressive alcoholic liver damage correlates with increased
epigenetic aging, as longitudinal liver biopsy samples from
individuals across the life span are not available to our
knowledge. Although both liver datasets show age accel-
eration in alcohol cirrhosis, future larger studies are
needed that in particular take into account various
demographic covariates as well as cell-specific analyses to
confirm this finding.
ALC is strongly associated with degeneration of brain
tissue as well as premature cognitive decline3,4,27,28. Thus,
we expected to find positive age acceleration in PFC tis-
sue, rather than the negative age acceleration that we
observed. However, there may be an explanation for these
findings; of our sample of 23 participants, 14 (61%) were
diagnosed with DSM-IV alcohol abuse and only nine
(39%) were diagnosed with ALC. Alcohol abuse is a
milder phenotype than ALC and is thus associated with
significantly lower levels of consumption. In fact, it is
possible that this sample is more representative of a
population that consumes alcohol at moderate levels,
which some research suggests may be associated with
healthy aging, reduced risk of coronary heart disease, and
reduced risk of cognitive decline and Alzheimer’s dis-
ease29–34. Future larger studies should confirm the effects
of alcohol on epigenetic age in PFC tissue and might also
explore additional brain regions, as results in our PFC
sample may not represent those in other regions.
Studying epigenetic aging in the blood is important, as
such results may be combined with those from other
tissues to eventually permit the use of DNA methylation
signatures in blood as a useful biomarker of aging and to
assess age acceleraton across the life span. The difference
in results between the NIAAA sample and Grady Trauma
project sample may be explained by the multi-year dif-
ference in age both within and between the two samples13.
In addition, the NIAAA sample was characterized by a
current ALC diagnosis, as well as current desire for
inpatient treatment, while the Grady Trauma Project was
characterized by a diagnosis of ALC anytime in one’s
Table 2 Average age acceleration (calculated using the
residual resulting from regressing DNA methylation age
on chronological age) and SE for samples
Average age
Acceleration
SE P-value
Case Control Case Control
NIAAA Blood 3.703 − 3.121 0.600 1.082 < 0.0001
GSE72680 Blood 0.081 − 0.063 0.484 0.456 0.8302
UMN LTCDS Liver 1.488 − 1.488 0.792 0.689 0.0069
GSE60753 Liver 0.864 − 0.547 2.390 1.074 0.5649
GSE49393 PFC − 0.577 0.577 0.574 0.659 0.1932
Note. Boldface indicates significance. Average age acceleration differed
significantly in the NIAAA blood sample and the UMN liver sample.
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lifetime. Thus, the NIAAA sample may represent a more
severe phenotype than the Grady Trauma project sample.
In fact, previous research indicates that differences in
genome-wide DNA methylation in individuals with ALC
and controls may be diminished following periods of
abstinence35. In addition, false reporting is common when
patients are asked to self-report alcohol use, and may
significantly influence the make-up of the case and con-
trol groups. This highlights the importance of developing
useful biomarkers to measure alcohol use36. Finally, the
Grady Trauma project was primarily a study of childhood
trauma, which may explain the small difference between
cases and controls. We did not control for this possible
covariate but it might have an effect on our results as a
previous epigenetic clock analysis using this data found
that cumulative lifetime stress was associated with accel-
erated aging37.
Further analyses would benefit from increased statistical
power. Many of our datasets had sample sizes ranging
from 25 to 50 individuals per group, which may partially
explain or influence these findings. In addition, clinical
heterogeneity remains a concern for studies of individuals
ALC+
(n=59)
ALC-
(n=70)
-4
-2
0
2
4
6
A
ge
A
cc
el
er
at
io
n
****
20 30 40 50 60
0
20
40
60
Chronological Age
D
N
A
M
et
hy
la
tio
n
A
ge
ALC+ (n=59)
ALC- (n=70)
ALC+
(n=143)
ALC-
(n=186)
-0.5
0.0
0.5
A
ge
A
cc
el
er
at
io
n
20 40 60 80
20
40
60
80
Chronological Age
D
N
A
M
et
hy
la
tio
n
A
ge
ALC- (n=186)
ALC+ (n=143)
(a)
(b)
Fig. 1 Age acceleration in blood. (a) NIAAA blood sample. (b) Grady Trauma Project (GSE72680) blood sample. Bar plots show average age
acceleration and 1 SE, as reported in Table 2. Scatter plots show chronological age vs. DNA methylation age and a line in which DNA methylation age
was regressed on chronological age. Points lying above the line exhibit negative age acceleration and points lying below the line exhibit positive age
acceleration. In both samples, age acceleration was positive in cases and negative in controls. Average age acceleration differed significantly (p <
0.0001) between cases and controls in the NIAAA sample, but not in the Grady Trauma Project sample
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with substance use disorders and the comparison of
multiple datasets can be problematic. For example, the
average chronological age in the NIAAA blood sample
was approximately 15 years younger than that of the
postmortem PFC sample and two liver cirrhosis samples.
In addition, ALC has been shown to be associated with a
multitude of comorbidities including cardiovascular dis-
ease, liver disease, smoking, and other substance use
disorders, as well as psychiatric disorders, such as major
depressive disorder and bipolar I disorder1. Previous
studies suggest that comorbidities and other lifestyle
factors, in combination with the medication used to treat
them, are likely to influence epigenetic aging and should
be controlled for in future analyses13,15.
Given that the epigenetic clock is valid across different
tissue types, collecting blood, liver, and postmortem brain
tissue samples from the same individuals would not only
remedy this problem of clinical heterogeneity, but also
allow us to take full advantage of the capabilities of the
epigenetic clock. Furthermore, it would be beneficial to
acquire data on race and ethnicity and specific drinking
patterns/abstinence in these samples, as well as to create a
more equal balance of males and females, as recent
research has shown that both race and sex may play a role
in the epigenetic aging process13,38. Finally, future studies
of epigenetic aging in ALC might consider analysis of
longitudinal data, especially after a period of treatment or
sobriety, to investigate the stability of age acceleration in
different tissue types in this population.
In conclusion, the present study provided evidence that
epigenetic aging differs in blood and liver tissue of indi-
viduals with ALC compared to healthy volunteers.
Although there were limitations in this study, these results
warrant further investigation into the role of chronic,
heavy alcohol consumption in the aging process across
various tissue types.
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